|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC23
|
|
gptkbp:brand
|
Empliciti
|
|
gptkbp:CASNumber
|
947078-27-5
|
|
gptkbp:combinationTherapy
|
gptkb:dexamethasone
gptkb:lenalidomide
|
|
gptkbp:developedBy
|
gptkb:AbbVie
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:firstBook
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
elotuzumab
|
|
gptkbp:indication
|
relapsed or refractory multiple myeloma
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG1_kappa
|
|
gptkbp:mechanismOfAction
|
activates natural killer cells
induces antibody-dependent cellular cytotoxicity
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL2108706
DB12021
71244489
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
constipation
fatigue
cough
peripheral neuropathy
infusion reactions
|
|
gptkbp:target
|
gptkb:SLAMF7
|
|
gptkbp:UNII
|
6QY1D43K5T
|
|
gptkbp:usedFor
|
multiple myeloma
|
|
gptkbp:bfsParent
|
gptkb:CD307
gptkb:CD319
gptkb:CD380
|
|
gptkbp:bfsLayer
|
8
|